AG
NVCR icon

Aperio Group’s NovoCure NVCR Stock Holding History

Aperio Group’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$2.52M Buy
14,548
+3,656
+34% +$500K 0.01% 1129
2020
Q3 		$1.21M Sell
10,892
-927
-8% -$74.1K ﹤0.01% 1348
2020
Q2 		$701K Sell
11,819
-3,418
-22% -$225K ﹤0.01% 1592
2020
Q1 		$1.03M Buy
15,237
+1,052
+7% +$83.1K ﹤0.01% 1293
2019
Q4 		$1.2M Buy
14,185
+252
+2% +$20.3K ﹤0.01% 1345
2019
Q3 		$1.04M Buy
13,933
+3,776
+37% +$302K ﹤0.01% 1371
2019
Q2 		$642K Buy
10,157
+1,684
+20% +$85.3K ﹤0.01% 1643
2019
Q1 		$408K Buy
8,473
+792
+10% +$38.1K ﹤0.01% 1861
2018
Q4 		$257K Buy
7,681
+2,113
+38% +$77.3K ﹤0.01% 2019
2018
Q3 		$292K Buy
+5,568
New +$222K ﹤0.01% 2025
2017
Q1 		– Sell
-20,503
Closed -$161K – 2153
2016
Q4 		$161K Buy
+20,503
New +$165K ﹤0.01% 2039

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Aperio Group's NVCR Position: Q4 2020 in Review

Aperio Group increased its NovoCure (NVCR) stake by 34% in Q4 2020, buying an estimated $500K and bringing the position to 14,548 shares worth $2.52M. The position accounts for 0.01% of the portfolio, ranked #1129.

Aperio Group first reported a position in NVCR in Q4 2016 and has held it in 11 quarters since. 357 funds tracked by Wall St. Rank hold NVCR as of Q4 2020.

  • Aperio Group held 14,548 shares of NovoCure worth $2.52M as of Q4 2020.
  • Aperio Group bought 3,656 NovoCure shares in Q4 2020, an estimated $500K.
  • NovoCure made up 0.01% of Aperio Group's portfolio in Q4 2020, its #1129 holding.
  • Aperio Group first reported a position in NovoCure in Q4 2016 and has held it in 11 quarters since.
  • 357 funds tracked by Wall St. Rank held NovoCure as of Q4 2020.

Based on Aperio Group's 13F filing for Q4 2020, filed 5 Feb 2021.